Conversion to Sandimmun Neoral in stable renal transplant recipients over 1 year: hepatitis, liver dysfunction, dosing intervals, and therapeutic ranges.
Hsieh
H
H
Department of Urology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Chien
Y S
YS
Hsu
K T
KT
Chung
H M
HM
D000284:Administration, Oral; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D016572:Cyclosporine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006506:Hepatitis A / Q000150:complications; D006509:Hepatitis B / Q000150:complications; D006514:Hepatitis B Surface Antigens / Q000097:blood; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D008099:Liver / Q000187:drug effects; D008111:Liver Function Tests; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D012189:Retrospective Studies
D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase